Impact of hepatitis C virus infection on buprenorphine dose in pregnancy: 649

Abstract

649 Impact of hepatitis C virus infection on buprenorphine dose in pregnancy Misty L. McDowell, Tiffany R. Tonismae, James E. Slaven, Sara K. Quinney, Anthony L. Shanks, Tara D. Benjamin Indiana University, Indianapolis, IN OBJECTIVE: Buprenorphine (BUP) is the preferred medication for opioid maintenance therapy in pregnancy and is primarily metabolized in the liver. Given that hepatitis C virus (HCV) infection is common in opiate dependent individuals, we sought to determine whether liver dysfunction related to HCV infection impacts the dose of BUP needed during pregnancy. STUDY DESIGN: A retrospective cohort study of 266 pregnancies with antenatal exposure to BUP from 2015-2018 at a single center.